Previous 10 | Next 10 |
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients, including addressing unmet need in patients with low-medium FolRα expression P...
2023-12-29 16:11:47 ET Summary Positive results achieved from phase 1 dose expansion study using luveltamab tazevibulin for the treatment of patients with FRa-positive endometrial cancer. Phase 1 dose expansion study, using luveltamab tazevibulin in FRa-positive endometrial cancer...
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor webcast to highlig...
– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in combination – – Luvelta was generally well-tolerated – ...
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will ...
2023-11-30 12:24:56 ET DENVER, Colo., Nov. 30, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; VinFast Auto Ltd (NASDAQ: VFS), Minim Inc (NASDAQ: MINM), Smart for Life Inc (NASDAQ: SMFL), Ampio Pha...
2023-11-30 12:17:22 ET More on AbbVie, ImmunoGen, etc. AbbVie: Get Ready For More Painful Downside AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time Biggest stock movers today: Sna...
2023-11-30 10:00:02 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble For further details see: Redhill Biopharma, Ampio Pharmaceuticals among healthcare movers
2023-11-30 08:06:09 ET Aditxt ( ADTX ) +66% . Clearmind Medicine ( CMND ) +63% . Ampio Pharmaceuticals ( AMPE ) +63% . Smart for Life ( SMFL ) +29% . China SXT Pharmaceuticals ( SXTC ) +28% . VinFast Auto ( VFS ) ...
-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial M...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., a...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...